Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
Roxee is still reviewing source support for this medication profile.
Roxee has safety or ingredient evidence for this medication, but a regulatory product/application match is still pending.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Generic profile • Source coverage pending
Species: Both
Approval status: Source coverage pending. Roxee has limited supporting content for this record, but no on-page official FDA animal-drug document is linked yet. Treat it as source-limited until the ETL backfill adds official coverage.
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus. Species commonly shown: Both.
Senvelgo (velagliflozin oral solution) is approved in cats for control of hyperglycemia associated with diabetes mellitus.
Top reported reactions (openFDA): Vomiting, Death, Injection site swelling, Not eating, Lack of efficacy - NOS, Tachycardia.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
Your vet decides this. Here's what owners typically ask/watch for.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Hydromorphone; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Elevated renal parameters (1 reports), Dysphoria (1 reports), Dull (1 reports)
Digestive (3), Skin & allergy (1), Neurologic (2), Behavior (2)
Cat (22 reports), Dog (10 reports)
Domestic Shorthair (2), Siberian Husky (1), Persian (1), ['Pointing Dog - Hungarian Short-haired (Vizsla)', 'Retriever - Labrador'] (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Hydromorphone fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
wobbly/unsteady walking, Loss of appetite, Elevated renal parameters
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: April 15, 2026, 10:04 AM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2025-12-09 · MSK · MSK
Received 2025-11-25 · MSK · MSK
Received 2025-11-19 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Neurologic | 1 | Cat | 1 | |
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Neurologic | 1 | Cat | 1 |
Species coverage: Cat (22) Dog (10)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Neurologic | Cat | Serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Skin & allergy | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Digestive | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Neurologic | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Digestive | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Behavior | Dog | Serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 |
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Diagnosis-code mappings are not available for this medication yet.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Every non-trivial field is expected to include provenance and update timestamps.
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Skin & allergy.
Showing top 5 for Neurologic.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Dog, Siberian Husky, Male, 9 year, 21.682 kilogram • Drug: MSK, Unassigned, Intramuscular • Reactions: Injection site lesion, Crust, Injection site ulcer, Injection site erythema, Injection site discharge NOS • Outcome: Ongoing
Cat, Persian, Male, 10.83 year, 4.67 kilogram • Drug: MSK, Unknown • Reactions: Hair loss at application site, Defect Unknown/Not Specified • Outcome: Ongoing
Cat, Domestic Shorthair, Male, 3 year, 4.3 kilogram • Drug: MSK, Unknown • Reactions: Tiredness (lethargy), Dull, Behavioral disorder (unspecified), Shallow breathing, Death • Outcome: Died
Cat, Domestic Shorthair, Male, 12 month, 4.354 kilogram • Drug: MSK • Reactions: Local swelling, Death • Outcome: Died
Dog, ['Pointing Dog - Hungarian Short-haired (Vizsla)', 'Retriever - Labrador'], Male, 8 year, 40.415 kilogram • Drug: MSK, Injection, Intramuscular, Dose: 1.60 mL per dose, Frequency: 1 per day • Reactions: Application site scar, Injection site alopecia, Injection site reaction NOS, Injection site nodule, Mast cell tumour… • Outcome: Outcome Unknown
Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Other • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown
Dog, Portuguese Water Dog, Female, 6 year, 23.406 kilogram • Drug: MSK, Intramuscular • Reactions: Loss of appetite, Injection site itching, Swelling NOS, Tiredness (lethargy), Injection site mucopurulent discharge… • Outcome: Ongoing
Dog, ['Mastiff (unspecified)', 'Dog (unknown)'], Female, 3 year, 35.834 kilogram • Drug: MSK, Injection, solution, Unknown • Reactions: Urinary incontinence • Outcome: Ongoing
Data source: FDA openFDA Animal & Veterinary adverse event reports.
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.